---
title: "Teclistamab vs lenalidomide–dexamethasone in high-risk smoldering multiple myeloma: randomized pha"
id: "nature-1-teclistamab-versus-lenalidomide-dexamethasone-in-high-risk-smoldering-multiple"
canonical_url: "https://medichelpline.com/clinical-feed/nature-1-teclistamab-versus-lenalidomide-dexamethasone-in-high-risk-smoldering-multiple"
content_type: "clinical_feed_article"
specialty: "Oncology"
source_name: "Nature Medicine"
source_url: "https://www.nature.com/articles/s41591-026-04642-w"
published_at: "2026-09-11T11:12:44.000Z"
evidence_level: "Journal Feed"
license: "CC-BY-NC-4.0 / Informational Use"
---
# Teclistamab vs lenalidomide–dexamethasone in high-risk smoldering multiple myeloma: randomized pha
## Provenance & Clinical Metadata
- **Canonical URL:** https://medichelpline.com/clinical-feed/nature-1-teclistamab-versus-lenalidomide-dexamethasone-in-high-risk-smoldering-multiple
- **Specialty:** [Oncology](https://medichelpline.com/clinical-feed/oncology.md)
- **Primary Source:** Nature Medicine
- **Source URL:** [Original Journal Publication](https://www.nature.com/articles/s41591-026-04642-w)
- **Published At:** 2026-09-11T11:12:44.000Z
- **Evidence Rating:** Journal Feed
## Executive GIST (TL;DR)
- This randomized phase 2 ImmunoPRISM trial compared fixed-duration **teclistamab** (an anti-BCMA bispecific T-cell engager) against standard **lenalidomide–dexamethasone (Rd)** in patients with high-risk smoldering multiple myeloma (HR-SMM). - After a six-patient safety run-in, 59 patients were randomized 2:1: 45 to teclistamab and 14 to Rd. The predefined primary endpoint was **complete response (CR)** rate. - As of data cutoff 26 May 2026, teclistamab induced CR in 77.8% of treated patients versus 0% with Rd. - **Minimal residual disease (MRD) negativity at 10−5** was achieved in 82.2% of patients in the teclistamab arm. - At a median follow-up of 24.5 months, 2-year **progression-free survival (PFS)** was 92% with teclistamab versus 49% with Rd. Response rates, duration of response and time to progression (TTP) were all significantly improved with teclistamab. - Safety findings: mainly grade 1–2 **cytokine release syndrome (CRS)** in the teclistamab arm, no neurotoxicity reported, and similar rates of grade 3 infections between arms (20% teclistamab versus 21% Rd). No deaths occurred in either arm. - The authors conclude that single-agent teclistamab is a highly active immune-interception strategy in HR-SMM, supporting earlier use of bispecific antibodies. - Trial registration: ClinicalTrials.gov NCT05469893. Details such as exact eligibility criteria, full demographic breakdown, statistical plan specifics and longer-term follow-up beyond the reported median were not fully reported in the provided source.
## Clinical Analysis & Structured Key Points
## Your privacy, your choice We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media, as well as to allow video information to be shared for both marketing, analytics and editorial purposes. By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection. See our [privacy policy](https://www.nature.com/info/privacy) for more information on the use of your personal data. Manage preferences for further information and to change your choices. Accept all cookies Reject optional cookies [Skip to main content](https://www.nature.com/articles/s41591-026-04642-w#content) Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript. Advertisement [ ![Nature Medicine](https://media.springernature.com/full/nature-cms/uploads/product/nm/header-95e59e63930e5d6009bad2c23a42ab2d.svg) ](https://www.nature.com/nm) * [ View all journals ](https://www.nature.com/siteindex) * [ Saved research ](https://www.nature.com/saved-research) * [ Search ](javascript:;) ## Search Search articles by subject, keyword or author Show results from All journals This journal Search [ Advanced search ](https://www.nature.com/search/advanced) ### Quick links * [Explore articles by subject](https://www.nature.com/subjects) * [Find a job](https://www.nature.com/naturecareers) * [Guide to authors](https://www.nature.com/authors/index.html) * [Editorial policies](https://www.nature.com/authors/editorial_policies/) * [Log in](https://idp.nature.com/auth/personal/springernature?redirect_uri=https://www.nature.com/articles/s41591-026-04642-w) * [ Content Explore content ](javascript:;) ## Explore content * [ Research articles ](https://www.nature.com/nm/research-articles) * [ Reviews & Analysis ](https://www.nature.com/nm/reviews-and-analysis) * [ News & Comment ](https://www.nature.com/nm/news-and-comment) * [ Podcasts ](https://www.nature.com/nm/podcast) * [ Current issue ](https://www.nature.com/nm/current-issue) * [ Collections ](https://www.nature.com/nm/collections) * [Follow us on Facebook ](https://www.facebook.com/Nature-Medicine-193691346949/) * [Follow us on X ](https://twitter.com/naturemedicine) * [Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) * [ About the journal ](javascript:;) ## About the journal * [ Aims & Scope ](https://www.nature.com/nm/aims) * [ Journal Information ](https://www.nature.com/nm/journal-information) * [ Journal Metrics ](https://www.nature.com/nm/journal-impact) * [ About the Editors ](https://www.nature.com/nm/editors) * [ Research Cross-Journal Editorial Team ](https://www.nature.com/nm/research-cross-journal-editorial-team) * [ Reviews Cross-Journal Editorial Team ](https://www.nature.com/nm/reviews-cross-journal-editorial-team) * [ Statistical Advisory Panel ](https://www.nature.com/nm/statistics-advisory-panel) * [ Our publishing models ](https://www.nature.com/nm/our-publishing-models) * [ Editorial Values Statement ](https://www.nature.com/nm/editorial-values-statement) * [ Editorial Policies ](https://www.nature.com/nm/editorial-policies) * [ Content Types ](https://www.nature.com/nm/content) * [ Web Feeds ](https://www.nature.com/nm/web-feeds) * [ Contact ](https://www.nature.com/nm/contact) * [ Publish with us ](javascript:;) ## Publish with us * [ Submission Guidelines ](https://www.nature.com/nm/submission-guidelines) * [ For Reviewers ](https://www.nature.com/nm/for-reviewers) * [ Language editing services ](https://authorservices.springernature.com/go/sn/?utm_source=For+Authors&utm_medium=Website_Nature&utm_campaign=Platform+Experimentation+2022&utm_id=PE2022) * [Open access funding](https://www.nature.com/nm/open-access-funding) * [Submit manuscript ](https://mts-nmed.nature.com/cgi-bin/main.plex) * [ Sign up for alerts ](https://journal-alerts.springernature.com/subscribe?journal_id=41591) * [ RSS feed ](https://www.nature.com/nm.rss) 1. [nature](https://www.nature.com/) 2. [nature medicine](https://www.nature.com/nm) 3. [articles](https://www.nature.com/nm/articles?type=article) 4. article Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial [ Download PDF ](https://www.nature.com/articles/s41591-026-04642-w.pdf) [ Download PDF ](https://www.nature.com/articles/s41591-026-04642-w.pdf) * Article * [Open access](https://www.springernature.com/gp/open-science/about/the-fundamentals-of-open-access-and-open-research) * Published: 11 September 2026 # Teclistamab versus lenalidomide-dexamethasone in high-risk smoldering multiple myeloma: a randomized phase 2 trial * [Omar Nadeem](https://www.nature.com/articles/s41591-026-04642-w#auth-Omar-Nadeem-Aff1-Aff2) [ORCID: orcid.org/0000-0002-4124-4277](https://orcid.org/0000-0002-4124-4277)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2) [na1](https://www.nature.com/articles/s41591-026-04642-w#na1), * [David M. Cordas dos Santos](https://www.nature.com/articles/s41591-026-04642-w#auth-David_M_-Cordas_dos_Santos-Aff1-Aff2) [ORCID: orcid.org/0000-0002-9198-8338](https://orcid.org/0000-0002-9198-8338)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2) [na1](https://www.nature.com/articles/s41591-026-04642-w#na1), * [Sophie Magidson](https://www.nature.com/articles/s41591-026-04642-w#auth-Sophie-Magidson-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Jeffrey Matous](https://www.nature.com/articles/s41591-026-04642-w#auth-Jeffrey-Matous-Aff3)[3](https://www.nature.com/articles/s41591-026-04642-w#Aff3), * [Eva Medvedova](https://www.nature.com/articles/s41591-026-04642-w#auth-Eva-Medvedova-Aff4)[4](https://www.nature.com/articles/s41591-026-04642-w#Aff4), * [Elizabeth O’Donnell](https://www.nature.com/articles/s41591-026-04642-w#auth-Elizabeth-O_Donnell-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Robert A. Redd](https://www.nature.com/articles/s41591-026-04642-w#auth-Robert_A_-Redd-Aff5)[5](https://www.nature.com/articles/s41591-026-04642-w#Aff5), * [Yuxin Liu](https://www.nature.com/articles/s41591-026-04642-w#auth-Yuxin-Liu-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Shonali Midha](https://www.nature.com/articles/s41591-026-04642-w#auth-Shonali-Midha-Aff1-Aff2) [ORCID: orcid.org/0000-0003-4948-5507](https://orcid.org/0000-0003-4948-5507)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Adam S. Sperling](https://www.nature.com/articles/s41591-026-04642-w#auth-Adam_S_-Sperling-Aff6) [ORCID: orcid.org/0000-0002-9369-4413](https://orcid.org/0000-0002-9369-4413)[6](https://www.nature.com/articles/s41591-026-04642-w#Aff6), * [Frances Arters](https://www.nature.com/articles/s41591-026-04642-w#auth-Frances-Arters-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Christine Davie](https://www.nature.com/articles/s41591-026-04642-w#auth-Christine-Davie-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Caroline Ricciardi](https://www.nature.com/articles/s41591-026-04642-w#auth-Caroline-Ricciardi-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Rosa Toenges](https://www.nature.com/articles/s41591-026-04642-w#auth-Rosa-Toenges-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Nayda Bidikian](https://www.nature.com/articles/s41591-026-04642-w#auth-Nayda-Bidikian-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Subear Hussein](https://www.nature.com/articles/s41591-026-04642-w#auth-Subear-Hussein-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Jean-Baptiste Alberge](https://www.nature.com/articles/s41591-026-04642-w#auth-Jean_Baptiste-Alberge-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Sungjae Kim](https://www.nature.com/articles/s41591-026-04642-w#auth-Sungjae-Kim-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Lorena Pantano-Rubino](https://www.nature.com/articles/s41591-026-04642-w#auth-Lorena-Pantano_Rubino-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Francesco Corrado](https://www.nature.com/articles/s41591-026-04642-w#auth-Francesco-Corrado-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Hannah Ashton](https://www.nature.com/articles/s41591-026-04642-w#auth-Hannah-Ashton-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Daniel Addonizio](https://www.nature.com/articles/s41591-026-04642-w#auth-Daniel-Addonizio-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Siham Mohamed](https://www.nature.com/articles/s41591-026-04642-w#auth-Siham-Mohamed-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Ashlee Sturtevant](https://www.nature.com/articles/s41591-026-04642-w#auth-Ashlee-Sturtevant-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Marjorie Marto](https://www.nature.com/articles/s41591-026-04642-w#auth-Marjorie-Marto-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Amy Bergeron](https://www.nature.com/articles/s41591-026-04642-w#auth-Amy-Bergeron-Aff1-Aff2)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Francesco Malfona](https://www.nature.com/articles/s41591-026-04642-w#auth-Francesco-Malfona-Aff2)[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Kevin Panaro](https://www.nature.com/articles/s41591-026-04642-w#auth-Kevin-Panaro-Aff2) [ORCID: orcid.org/0009-0004-7430-1399](https://orcid.org/0009-0004-7430-1399)[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Paul G. Richardson](https://www.nature.com/articles/s41591-026-04642-w#auth-Paul_G_-Richardson-Aff2)[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Jerome Ritz](https://www.nature.com/articles/s41591-026-04642-w#auth-Jerome-Ritz-Aff2) [ORCID: orcid.org/0000-0001-5526-4669](https://orcid.org/0000-0001-5526-4669)[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2), * [Lorenzo Trippa](https://www.nature.com/articles/s41591-026-04642-w#auth-Lorenzo-Trippa-Aff5) [ORCID: orcid.org/0000-0001-5218-5666](https://orcid.org/0000-0001-5218-5666)[5](https://www.nature.com/articles/s41591-026-04642-w#Aff5) & * … * [Irene M. Ghobrial](https://www.nature.com/articles/s41591-026-04642-w#auth-Irene_M_-Ghobrial-Aff1-Aff2) [ORCID: orcid.org/0000-0001-7361-3092](https://orcid.org/0000-0001-7361-3092)[1](https://www.nature.com/articles/s41591-026-04642-w#Aff1),[2](https://www.nature.com/articles/s41591-026-04642-w#Aff2) Show authors [_Nature Medicine_](https://www.nature.com/nm) (2026) [Cite this article](https://www.nature.com/articles/s41591-026-04642-w#citeas) [ Save article ](https://www.nature.com/articles/s41591-026-04642-w/save-research?_csrf=HEsk_DxkS5RsU8BdTs2wXap7BW_1Py7U) [ View saved research ](https://www.nature.com/saved-research) ## Abstract Teclistamab, a B cell maturation antigen-targeting bispecific antibody, has demonstrated substantial activity in relapsed multiple myeloma (MM), particularly in earlier lines of therapy, and may have higher efficacy in high-risk smoldering MM (HR-SMM) with a more functional immune system. In the randomized phase 2 ImmunoPRISM trial, we compared fixed-duration teclistamab with lenalidomide–dexamethasone (Rd) in HR-SMM. After a six-patient safety run-in, patients were randomized 2:1 to teclistamab or Rd. The primary endpoint was complete response (CR) rate. As of 26 May 2026, 59 patients were treated—45 received teclistamab and 14 received Rd. Teclistamab treatment induced a CR in 77.8% patients versus 0% with Rd, and minimal residual disease negativity at 10−5 in 82.2% patients. At a median follow-up of 24.5 months, 2-year progression-free survival was 92% with teclistamab versus 49% with Rd. Overall, response rates, duration of response and time to progression (TTP) were significantly improved in teclistamab compared to Rd. Toxicities in the teclistamab arm included grades 1–2 cytokine release syndrome, no neurotoxicity and no increase in grade 3 infections compared to Rd (20% versus 21%). No deaths occurred in either arm. Teclistamab represents a highly active immune-interception strategy for HR-SMM. ClinicalTrials.gov registration: [NCT05469893](https://clinicaltrials.gov/study/NCT05469893). ### Explore related subjects Discover the latest articles and news in related subjects. * [Cancer immunotherapy](https://www.nature.com/subjects/cancer-immunotherapy) * [Myeloma](https://www.nature.com/subjects/myeloma) * [Phase II trials](https://www.nature.com/subjects/phase-ii-trials) ## Main Teclistamab is an anti-B cell maturation antigen (BCMA) bispecific T-cell engager that is approved for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). In heavily pretreated patients, single-agent teclistamab has demonstrated clinically meaningful activity, although the durability of disease control remains limited in this advanced-disease setting[1](https://www.nature.com/articles/s41591-026-04642-w#ref-CR1 "Moreau, P. et al. Teclistamab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 387, 495–505 https://doi.org/10.1056/NEJMoa2203478 \(2022\)."),[2](https://www.nature.com/articles/s41591-026-04642-w#ref-CR2 "Tan, C. R. et al. Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma \(RRMM\): an International Myeloma Working Group study. Blood Cancer J. 15, 53 https://doi.org/10.1038/s41408-025-01259-z \(2025\)."),[3](https://www.nature.com/articles/s41591-026-04642-w#ref-CR3 "Mohan, M. et al. Teclistamab in relapsed refractory multiple myeloma: multi-institutional real-world study. Blood Cancer J. 14, 35 https://doi.org/10.1038/s41408-024-01003-z \(2024\)."),[4](https://www.nature.com/articles/s41591-026-04642-w#ref-CR4 "Dima, D. et al. Safety and efficacy of teclistamab in patients with relapsed/refractory multiple myeloma: a real-world experience. Transplant. Cell Ther. 30, 308.e1–308.e13 https://doi.org/10.1016/j.jtct.2023.12.016 \(2024\)."). In MajesTEC-1, median progression-free survival (PFS) was 11.8 months, a complete response (CR) or better was achieved in 39.4% patients and minimal residual disease (MRD) negativity was observed in 26.7% patients. More recently, teclistamab was approved in combination with daratumumab in RRMM patients after one to three prior lines of therapy, demonstrating higher MRD-negativity rates and improved PFS of 83% at 3 years compared with standard therapies[5](https://www.nature.com/articles/s41591-026-04642-w#ref-CR5 "Costa, L. J. et al. Teclistamab plus daratumumab in relapsed or refractory multiple myeloma. N. Engl. J. Med. 394, 739–752 https://doi.org/10.1056/NEJMoa2514663 \(2026\)."). Single-agent teclistamab also has recently demonstrated substantial improvement in outcomes compared to conventional regimens in RRMM after one to three prior lines of therapy, further supporting higher efficacy of earlier use of bispecific antibodies[6](https://www.nature.com/articles/s41591-026-04642-w#ref-CR6 "Mina, R. et al. MajesTEC-9: a phase 3 randomized study of teclistamab monotherapy vs investigator’s choice of pomalidomide, bortezomib, and dexamethasone or carfilzomib and dexamethasone \(PVd/Kd\) in patients \(pts\) with relapsed refractory multiple myeloma \(RRMM\). J. Clin. Oncol. 44, 7507 https://doi.org/10.1200/JCO.2026.44.16_suppl.7507 \(2026\)."). High-risk smoldering multiple myeloma (HR-SMM) is an asymptomatic plasma-cell neoplasm that shares recurrent genomic features with multiple myeloma (MM)[7](https://www.nature.com/articles/s41591-026-04642-w#ref-CR7 "Alberge, J.-B. et al. Genomic landscape of multiple myeloma and its precursor conditions. Nat. Genet. 57, 1493–1503 \(2025\)."),[8](https://www.nature.com/articles/s41591-026-04642-w#ref-CR8 "Aktas Samur, A. et al. Genomically smoldering multiple myeloma is not a distinct entity but a collection of monoclonal gammopathy of undetermined significance or multiple myeloma. J. Clin. Oncol. 44, 321–334 \(2026\)."),[9](https://www.nature.com/articles/s41591-026-04642-w#ref-CR9 "Maura, F. et al. Temporal genomic dynamics shape clinical trajectory in multiple myeloma. Nat. Genet. 57, 2203–2214 \(2025\).") and carries a high-risk of progression to overt MM based on established clinical and genomic criteria[10](https://www.nature.com/articles/s41591-026-04642-w#ref-CR10 "Pérez-Persona, E. et al. New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood 110, 2586–2592 https://doi.org/10.1182/blood-2007-05-088443 \(2007\)."),[11](https://www.nature.com/articles/s41591-026-04642-w#ref-CR11 "Mateos, M. V. et al. International Myeloma Working Group risk stratification model for smoldering multiple myeloma \(SMM\). Blood Cancer J. 10, 102 https://doi.org/10.1038/s41408-020-00366-3 \(2020\)."),[12](https://www.nature.com/articles/s41591-026-04642-w#ref-CR12 "Cowan, A. et al. Personalised progression prediction in patients with monoclonal gammopathy of undetermined significance or smouldering multiple myeloma \(PANGEA\): a retrospective, multicohort study. Lancet Haematol. 10, e203–e212 \(2023\)."),[13](https://www.nature.com/articles/s41591-026-04642-w#ref-CR13 "Dispenzier
## Related Clinical Research

- [Anwulignan induces pyroptosis and overcomes proteasome inhibitor resistance in multiple myeloma](https://medichelpline.com/clinical-feed/pubmed-42704369.md) (DOI: 10.1007/s10495-026-02426-8)
- [Global inequities in seminal studies underlying chemotherapy-induced nausea and vomiting guidelines](https://medichelpline.com/clinical-feed/pubmed-42601561.md) (DOI: 10.1007/s00520-026-11103-0)
- [FDA approves Zenbexus (iberdomide) for multiple myeloma, first of a novel drug class](https://medichelpline.com/clinical-feed/stat-news-1-stat-fda-approves-bristol-multiple-myeloma-treatment-marking-debut-of-novel.md)
- [HCT–ASCT validated as superior consolidation versus non‑myeloablative chemoimmunotherapy for PCNSL](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-hct-asct-confirmed-as-standard-of-care-consolidation-therapy-for-pcnsl.md)
- [Integrating talquetamab regimens in early relapsed/refractory multiple myeloma: implications and o](https://medichelpline.com/clinical-feed/nature-reviews-clinical-oncology-0-more-options-more-questions-in-the-management-of-early-relapsed-and-or.md)

## Navigation
- [← Back to Oncology Feed](https://medichelpline.com/clinical-feed/oncology.md)
- [← All Clinical Specialties](https://medichelpline.com/clinical-feed.md)
## Medical & Regulatory Disclaimer

> [!CAUTION]
> MedicHelpline content is structured for research, educational, and professional discovery purposes. It does not constitute individual medical advice, clinical diagnosis, or treatment recommendations.
> Always verify dosing, contraindications, and regulatory alerts against official product labeling and primary regulatory sources before clinical decision-making.